

Sheet 1 of 2

Modified Form PTO-1449

Atty. Docket No.

Serial No.

A-665B

09/843,221

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Kostenuik, et al.

Filing Date

April 26, 2001

Group

1647

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
CS	A1	5,693,616	02 Dec 1997	Krstenansky et al.			
↓	A2	5,807,823	15 Sep 1998	Krstenansky et al.			
↓	A3	5,874,086	23 Feb 1999	Krstenansky et al.			
CS	A4	6,417,333 B1	09 Jul 2002	Bringhurst et al.			
	A5						
	A6						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES      NO
	B1						
	B2						

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**


CS	C1	Baumann et al., Response of Cortical Bone to Antiresorptive Agents and Parathyroid Hormone in Aged Ovariectomized Rats. BONE, 16(6): 247-253. (Feb 1995).
↓	C2	Berning et al., Tibolone and its effects on bone: a review. CLIMACTERIC, 4(2):120-136. (June 2001).
	C3	Crandall, C., Parathyroid Hormone for Treatment of Osteoporosis. ARCHIVES OF INTERNAL MEDICINE, 162: 2297-2309. (11 Nov 2002).
	C4	Hodsman, A. B. et al., Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. BONE AND MINERAL., 9(2): 137-152. (May 1990)
	C5	Hofbauer, L. C. et al., Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. ENDOCRINOLOGY, 140(10): 4382-4389. (Oct 1999)
	C6	Kostenuik, P. J. et al., OPG and PTH(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. ENDOCRINOLOGY, 142(10): 4295-4304. (Oct 2001)
	C7	Li, M. et al., Parathyroid Hormone Monotherapy and cotherapy with Antiresorptive Agents Restore Vertebral Bone Mass and Strength in Aged Ovariectomized Rates. BONE, 16(6): 629-635. (Jun 1995)
↓	C8	Morley, P. et al., Parathyroid Hormone: An Anabolic Treatment for Osteoporosis. CURRENT PHARMACEUTICAL DESIGN, 7(8): 671-687. (May 2001).
CS	C9	Reeve, J. et al., Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J. BONE MINR. METAB., 19(2): 102-114. (09 March 2001).

EXAMINER:

Date Considered:

2/17/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 01 2

Modified Form PTO-1449		Atty. Docket No. A-665B	Serial No. 09/843.221
<b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)		Applicant Kostenuik, et al.	
		Filing Date April 26, 2001	Group 1647

EXAMINER'S INITIALS

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

<i>CC</i>	C10	Rosen et al., CLINICAL REVIEW 123: HOT TOPIC Anabolic Therapy for Osteoporosis. THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 86(3): 957-964, (Mar 2001).
<i>CC</i>	C11	Tanizawa et al., Effects of human PTH (1-34) and bisphosphonate on the osteopenic rat model. TOXICOLOGY LETTERS. 102-103: 399-403, (Dec 1998).
<i>CC</i>	C12	Wronski, T. J., et al., Parathyroid Hormone is More Effective Than Estrogen or Bisphosphonates for Restoration of Lost Bone Mass in Ovariectomized Rats. ENDOCRINOLOGY, 132(2): 823-831, (Feb 1993)
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	C18	
	C19	
	C20	
	C21	
	C22	
	C23	
	C24	
	C25	
	C26	
	C27	
	C28	
	C29	
	C30	
	C31	

EXAMINER:

Date Considered:

*2/17/2004*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.